title: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.
abstract: Between 1988 and 2002, 758 children with acute myeloid leukaemia (AML) were treated on Medical Research Council (MRC) AML 10 and AML 12. MRC AML 10 tested the role of bone marrow transplantation following four blocks of intensive chemotherapy and found that while both allogeneic bone marrow transplant (allo-BMT) and autologous bone marrow transplant (A-BMT) significantly reduced the relapse risk (RR), this did not translate into a significant improvement in overall survival (OS). A risk group stratification based on cytogenetics and response to the first course of chemotherapy derived from MRC AML 10 was used to deliver risk-directed therapy in MRC AML 12. Allo-BMT was limited to standard and poor risk patients and A-BMT was not employed. Instead, the benefit of an additional block of treatment was tested by randomising children to receive either four or five blocks of treatment in total. While the results of MRC AML 12 remain immature, there appears to be no survival advantage for a fifth course of treatment. The 5 year OS, disease-free survival (DFS), event-free survival (EFS) and RR in MRC AML 12 are 66, 61, 56 and 35%, respectively; at present superior to MRC AML 10, which had a 5-year OS, DFS, EFS and RR of 58, 53, 49 and 42%, respectively. MRC AML trials employ a short course of triple intrathecal chemotherapy alone for CNS-directed treatment and CNS relapse is uncommon. Improvements in supportive care have contributed to improved outcomes and the number of deaths in remission fell between trials. Anthracycline-related cardiotoxicity remains a concern and the current MRC AML 15 trial tests the feasibility of reducing anthracycline dosage without compromising outcome by comparing standard MRC anthracycline-based consolidation with high-dose ara-C. MRC studies suggest that the role of allo-BMT is limited in 1st CR and that there may be a ceiling of benefit from current or conventional chemotherapy.
authors.affiliation: Royal Hospital for Sick Children, Glasgow, UK. brenda.gibson@yorkhill.scot.nhs.uk
authors.forename: B E S
authors.initials: BE
authors.lastname: Gibson
authors.forename: K
authors.initials: K
authors.lastname: Wheatley
authors.forename: I M
authors.initials: IM
authors.lastname: Hann
authors.forename: R F
authors.initials: RF
authors.lastname: Stevens
authors.forename: D
authors.initials: D
authors.lastname: Webb
authors.forename: R K
authors.initials: RK
authors.lastname: Hills
authors.forename: S S N
authors.initials: SS
authors.lastname: De Graaf
authors.forename: C J
authors.initials: CJ
authors.lastname: Harrison
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D024221:Antineoplastic Protocols / Q000592:standards*; D016026:Bone Marrow Transplantation / Q000401:mortality; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007278:Injections, Spinal; D007951:Leukemia, Myeloid / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction / Q000379:methods; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome